These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12076393)

  • 41. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
    Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
    J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
    Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
    Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
    J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
    Lim SG; Wai CT; Lee YM; Dan YY; Sutedja DS; Wee A; Suresh S; Wu YJ; Machin D; Lim CC; Fock KM; Koay E; Bowden S; Locarnini S; Ishaque SM
    Antivir Ther; 2006; 11(2):245-53. PubMed ID: 16640105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
    Gluud LL; Krogsgaard K; Gluud C
    Cochrane Database Syst Rev; 2007 Jul; 2002(2):CD002234. PubMed ID: 17636700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].
    Li MH; Xie Y; Wu YZ; Xu DZ; Lu ZM; Hou JL; Jia JD; Wang YM; Zhang SL; Ren H; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jul; 15(7):481-4. PubMed ID: 17669233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis.
    Kong LN; Qin B; Ma Q; Li L; Yao Y
    J Gastroenterol Hepatol; 2014; 29(7):1387-95. PubMed ID: 24548048
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medicinal herbs for hepatitis C virus infection.
    Liu JP; Manheimer E; Tsutani K; Gluud C
    Cochrane Database Syst Rev; 2001; 2001(4):CD003183. PubMed ID: 11687177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine.
    Hasan F; al-Khaldi J; Asker H; Varghese R; Siddique I; al-Shammali M; al-Kalaoui M; al-Nakib B
    Hepatogastroenterology; 2003; 50(54):2040-2. PubMed ID: 14696461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.